Last edition
News about "Apriori Bio"
Apriori Bio, A*STAR IDL Partner to Develop Next-Gen AI-Designed saRNA Flu Vaccines
Apriori Bio, a Flagship Pioneering company focused on creating variant-resilient vaccines, has announced a strategic research partnership with the ASTAR Infectious Diseases Labs (ASTAR IDL) to co-develop next-generation self-amplifying RNA (saRNA) vaccines for seasonal and pandemic influenza.
Apriori Bio | 19/11/2025 | By Darshana
Apriori Bio Partners with Francis Crick Institute to Advance Variant-Resilient Vaccine Research
Apriori Bio has partnered with the Francis Crick Institute to leverage AI-driven insights and the Crick’s Legacy Study for developing variant-resilient vaccines against current and emerging viral threats.
Apriori Bio | 14/08/2025 | By Mrinmoy Dey | 111
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy